Pratosartan is an angiotensin II receptor antagonist primarily used in the treatment of hypertension. It belongs to the class of medications known as sartans, which work by blocking the action of angiotensin II, a hormone that causes blood vessels to constrict, thereby lowering blood pressure. The chemical structure of Pratosartan features a biphenyl group and a carboxylic acid moiety, contributing to its pharmacological activity. It is characterized by its high selectivity for the angiotensin II receptor subtype 1 (AT1), which is crucial for its therapeutic effects. Pratosartan is typically administered orally and exhibits a favorable pharmacokinetic profile, including good bioavailability and a moderate half-life, allowing for once-daily dosing. Additionally, it is generally well-tolerated, with a side effect profile similar to other medications in its class, including dizziness, fatigue, and potential renal effects. As with all antihypertensives, monitoring of blood pressure and renal function is recommended during treatment.

Pratosartan

153804-05-8: 153804-05-8, 4(3H)-Cycloheptimidazolone, 5,6,7,8-tetrahydro-2-propyl-3-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-, 4(3H)-Cycloheptimidazolone, 5,6,7,8-tetrahydro-2-propyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-, 5,6,7,8-Tetrahydro-2-propyl-3-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-4(3H)-cycloheptimidazolone, Fw 7203, Kd 3-671, Kt 3-671, Kt 3671, Pratosartan, Pratosartan (JAN)

Pratosartan is a statin drug used to treat hypercholesterolemia and metabolic disorders. This drug has been shown to reduce the symptoms of these diseases, including muscle pain and weakness, fatigue, headache, and sexual dysfunction. Pratosartan belongs to a class of drugs called HMG-CoA reductase inhibitors that work by blocking the production of cholesterol in the liver. The chemical structure of Pratosartan can be found below.

Clinical studies have shown that this drug has an anti-oxidative effect on cancer cells. Pratosartan also inhibits the release of epidermal growth factor (EGF) from cancer cells in an animal study. This drug has been shown to have protective effects against bowel disease, such as inflammatory bowel disease or colitis, and against muscle cell proliferation associated with inflammatory bowel disease.

CAS 153804-05-8: Pratosartan

Pratosartan

Ref: 3D-DGA80405

Pratosartan

Ref: TM-T16573